Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
Khemayanto HidayatX DuB-M ShiPublished in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2019)
Cumulative real-world evidence does not support an association between the use of DPP-4i, GLP-1ra, or SGLT2i and the risk of fracture. Our findings, together with the cumulative evidence from RCTs, should reassure policy makers and medical practitioners that the use of these medications is unlikely to increase the risk of fracture among type 2 diabetes mellitus patients in general. Further studies need to investigate the long-term impact of these drugs on the fracture risk, particularly in high-risk populations.
Keyphrases
- healthcare
- end stage renal disease
- hip fracture
- ejection fraction
- newly diagnosed
- chronic kidney disease
- primary care
- public health
- rheumatoid arthritis
- prognostic factors
- type diabetes
- metabolic syndrome
- systemic sclerosis
- disease activity
- systemic lupus erythematosus
- case control
- patient reported
- interstitial lung disease